Background: Apart from PD-L1 and mutational load, there are no genetic predictive biomarkers for checkpoint inhibitors treatment. In this study, gene embedding, a machine learning technique, was used to single out related genes of immune checkpoint proteins (i.e. PD-1, PD-L1, CTLA-4) as new potential predictors for such responders. Methods: TCGA RNASeqV2 level 3 RSEM normalized read counts (January 2016) were downloaded from the Broad Institute TCGA GDAC Firehose. A shallow neural network, aka embedding layers for samples and genes, were trained using log2 transformed data. Neighbors closeness were evaluated by euclidean distance. The model was kept blind from any additional information, including cancer types, protein-protein interactions and gene ontologies. Results: Gene expressions of 13045 samples from 36 cancer types were embedded into 50-dimension space, while cancer types were learnt by the model without supervision. Immunotherapy responders and non-responders were stimulated from melanoma (SKMC) and lung squamous cell carcinoma (LUSC) data, and hepatocellular carcinoma and prostate cancer data respectively. 9 genes (TNFRSF8, CLEC10A, FCN1, CD8B, SLA2, IL2RA, CTLA4, GZMH), 3 (CD101, LOC154761, RNF152) genes, and 6 (SH2D1A, MEI1, PDCD1, GFI1, SIT1, SIRPG) genes were found to be closely related neighbors with PD-1, PD-L1, and CTLA-4 respectively in responders but not in nonresponders. All neighbors were neither co-expressed in SKMC/LUSC dataset nor indicated as interacting partners on existing databases (BioGRID, MINT, iRefWeb, STRING, HPRD and Reactome). 88.8% genes were evidenced as either directly related to checkpoint proteins and/or T cells activation in literature. Further evaluation of the role of identified targets in immune checkpoint blockade therapy would be warranted. Conclusions: We identified potential biomarker candidates for immune checkpoint blockade therapy by TCGA data mining and demonstrated the utility of gene embedding learned from big gene expression dataset as a powerful tool to uncover gene relationships that may not be discovered otherwise without prior knowledge on functional interactions. We have now genotyped 4 rare variants using the same cohort. Methods: Blood samples were available from 2183 patients treated with first line oxaliplatin-5FU 6 cetuximab. We assayed IVS14 þ 1G>A [rs3918290], Asp949Val
Primary endpoint was dose reduction or delay in chemotherapy in the first 12 weeks of treatment due to any toxicity except neuropathy. Secondary endpoints were grade 2 versus grade <2 for neutropenia, lethargy, Nausea & Vomiting (N&V), diarrhoea, stomatitis, Hand-Foot Syndrome (HFS) and infection. Results: Two rare variants were associated with toxicity (OR (95% CI)): Asp949Val with neutropenia 3.2 (1.2-8.2) P ¼ 0.019, N&V 3.4 (1.5-7.3) P ¼ 0.002, diarrhoea 4.6 (2.1-10.1) P < 0.001 and infection 5.5 (1.3-24.2) P ¼ 0.024; IVS14 þ 1G>A with lethargy 5.3 (1.9-14.9) P ¼ 0.002, diarrhoea 4.4 (1.7-11.0) P ¼ 0.002, stomatitis 4.6 (1.7-12.6) P ¼ 0.003, HFS 3.8 (1.2-11.8) P ¼ 0.021 and infection 19.2 (5.0-73.8) P < 0.001. MAF was 0.007 and 0.005, respectively. The effect on toxicity for our 2 common variants was not as marked (OR (95% CI)): Cys29Arg 0.8 (0.7-1.0) P ¼ 0.008 (protective) and Val732Ile 1.6 (1.1-2.1) P ¼ 0.006 for the primary endpoint. Conclusions: We have validated 2 mutations, Asp949Val and IVS14 þ 1G>A, as predictors for 5FU toxicity in a large cohort of patients and recommend they should be screened for. Our data suggest that common DPYD variants are also associated with toxicity but not to the same level seen with rare ones. While the presence of a single common variant is not an indication for dose modification, the presence of multiple variants in a patient might be. Further work is needed to establish what combinations of common DPYD variants would necessitate 5FU dose alteration. Legal entity responsible for the study: Cardiff University and MRC CTU. Background: NTRK gene fusions resulting in the elevated expression of TRK kinases were discovered in a wide variety of tumor types but generally at a low frequency. TRK inhibitors such as LOXO-101 and entrectinib had remarkable and durable antitumor activities in patients (pts) with TRK fusion-positive cancers, regardless of age or tumor type. Methods: FFPE tumor samples of over 3700 Chinese solid tumor pts were collected for NGS-based assay. We measured the gene fusions, mutations, and copy number alterations in tumor tissue against matched blood. Pan-Trk IHC testing was performed on five NTRK1 fusions. Results: 12 pts were idendified as NTRK fusion positive, which accounted to approximately 0.3% of the Chinese solid tumor pts in our cohort. Seven out of 12 pts harbored NTRK1 fusions with 6 partners, and the remaining ones were NTRK3 fusions with 2 partners. The half fusions with novel partner genes or breakpoints were defined as likely fusions. The tumor types of pts with NTRK fusions included NSCLC, colorectal cancer (CRC), prostate cancer and fibrosarcoma. NTRK fusions were more likely t occur in NSCLC and CRC, which accouted for 0.3% and 1.4%, respectively. Three predicted likely fusions and two known fusions were selected to perform pan-Trk IHC assay, and four were IHC positive. One known TPR-NTRK1 fusion not detected by IHC, which highlighted the necessity to use NGS to detect NTRK fusions due to higher sensitivity and capability. NTRK fusions were not always mutually exclusive with driver mutations. Three lung cancer pts with NTRK fusions also harbored EGFR-sensitive mutations. 
